Damora Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights

The Phase 1/1b CLARITY-101 clinical trial has been launched to study DMR-001 in individuals suffering from mutant calreticulin (mutCALR)-driven essential thrombocythemia (ET) and myelofibrosis (MF). This trial aims to assess the effectiveness and safety of DMR-001 in treating these conditions.